Publication: Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress.
Loading...
Identifiers
Date
2022-03-17
Authors
Torrente-Lopez, Anabel
Hermosilla, Jesus
Salmeron-Garcia, Antonio
Cabeza, Jose
Navas, Natalia
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI AG
Abstract
Nivolumab, formulated in the medicine Opdivo® (10 mg/mL), is a therapeutic monoclonal antibody (mAb) used in the treatment of different types of cancer. Currently, there is insufficient knowledge about the behaviour of this protein with regards to the risk associated with its routine handling or unintentional mishandling, or when subjected to stress conditions in hospitals. These conditions can be simulated in forced degradation studies, which provide an in-depth understanding of the biophysical and biochemical properties of mAbs. In this study, we carried out a physicochemical and functional characterisation of nivolumab, which was subjected to various stress conditions: heat, freeze/thaw cycles, agitation, light exposure and high hypertonic solution. We used a wide range of analytical techniques: Far-UV CD, IT-FS, DLS, SE/UHPLC(UV)-[Native]MS, and ELISA. The results show that exposure to light was the stress test with the greatest impact on the samples, revelling the formation of non-natural dimers and a different isoform profile. In addition, nivolumab (Opdivo®) demonstrated stability up to 60 °C (1 h). As regards functionality all the nivolumab (Opdivo®) stressed samples were found to be stable except for those subjected to light and agitation, and to a lesser extent, those subjected to FTC 5 and NaCl stresses.
Description
MeSH Terms
Nivolumab
Antibodies, Monoclonal
Sodium Chloride
Chromatography, High Pressure Liquid
Exercise Test
Neoplasms
Protein Isoforms
Enzyme-Linked Immunosorbent Assay
Hospitals
Antibodies, Monoclonal
Sodium Chloride
Chromatography, High Pressure Liquid
Exercise Test
Neoplasms
Protein Isoforms
Enzyme-Linked Immunosorbent Assay
Hospitals
DeCS Terms
Anticuerpos monoclonales
Cloruro de sodio
Cromatografía líquida de alta presión
Ensayo de inmunoadsorción enzimática
Hospitales
Isoformas de proteínas
Neoplasias
Nivolumab
Prueba de esfuerzo
Cloruro de sodio
Cromatografía líquida de alta presión
Ensayo de inmunoadsorción enzimática
Hospitales
Isoformas de proteínas
Neoplasias
Nivolumab
Prueba de esfuerzo
CIE Terms
Keywords
UHPLC-MS, comprehensive analytical characterisation, forced degradation, isoform profile, nivolumab
Citation
Torrente-López A, Hermosilla J, Salmerón-García A, Cabeza J, Navas N. Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress. Pharmaceutics. 2022 Mar 23;14(4):692